A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes
- PMID: 22169079
- DOI: 10.1016/j.eururo.2011.11.053
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes
Abstract
Context: The optimal management strategy for men with newly diagnosed clinically localized prostate cancer remains a matter of debate. Numerous series have reported cancer control and quality-of-life (QoL) outcomes following treatment with radical prostatectomy (RP).
Objective: Critically review published oncologic and functional outcomes after RP, and evaluate factors associated with these outcome measures.
Evidence acquisition: A review of the literature was performed using the Medline and Web of Sciences databases. Relevant reports published between 1980 and 2011 identified using the keywords prostate cancer, radical prostatectomy, prostate-specific antigen, biochemical recurrence, incontinence, and erectile dysfunction were reviewed and summarized.
Evidence synthesis: Cancer control rates following RP largely depend on the definition of treatment efficacy. While up to 40% of men have been reported to experience postoperative biochemical recurrence on long-term follow-up, death from prostate cancer has been noted in <10% of men at 15 yr after surgery in contemporary series. For men with high-risk disease, surgery affords pathologic staging, thereby facilitating the selective application of secondary therapies, and has been associated with decreased mortality risk versus radiation in retrospective series. Reported functional outcomes after surgery, particularly urinary continence and erectile dysfunction, have varied greatly to date. These assessments have been limited by nonstandardized reporting methodology. The use of robot-assisted radical prostatectomy has increased in recent years, and while follow-up is thus far short, available data do not suggest the superiority of either approach in terms of functional or oncologic outcomes.
Conclusions: RP is associated with excellent long-term cancer control. Continued efforts to conduct prospective assessments of postoperative functional outcomes are necessary using validated QoL instruments. The importance of surgical approach will also require further study, incorporating comparative oncologic, functional, and economic data.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Radical prostatectomy for long-term functional and oncologic outcomes.Eur Urol. 2012 Apr;61(4):676-8. doi: 10.1016/j.eururo.2012.01.004. Epub 2012 Jan 11. Eur Urol. 2012. PMID: 22257423 No abstract available.
Similar articles
-
20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.BJU Int. 2012 Dec;110(11):1709-13. doi: 10.1111/j.1464-410X.2012.11372.x. Epub 2012 Aug 30. BJU Int. 2012. PMID: 22934913
-
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.BJU Int. 2005 Apr;95(6):751-6. doi: 10.1111/j.1464-410X.2005.05394.x. BJU Int. 2005. PMID: 15794776
-
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.J Urol. 2000 Jun;163(6):1802-7. J Urol. 2000. PMID: 10799186
-
Laparoscopic radical prostatectomy: a critical analysis of surgical quality.Eur Urol. 2006 Apr;49(4):625-32. doi: 10.1016/j.eururo.2006.01.018. Epub 2006 Jan 31. Eur Urol. 2006. PMID: 16488072 Review.
-
Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.Eur Urol. 2012 Jan;61(1):112-27. doi: 10.1016/j.eururo.2011.09.027. Epub 2011 Oct 6. Eur Urol. 2012. PMID: 22001105 Review.
Cited by
-
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer.Urol Oncol. 2017 Feb;35(2):51-58. doi: 10.1016/j.urolonc.2016.03.021. Epub 2016 Apr 28. Urol Oncol. 2017. PMID: 27133953 Free PMC article. Review.
-
Raised prostate-specific antigen alone may not be a true predictor in high-risk prostate cancer: A retrospective cohort analysis.Indian J Urol. 2022 Jan-Mar;38(1):22-28. doi: 10.4103/iju.iju_368_21. Epub 2022 Jan 1. Indian J Urol. 2022. PMID: 35136291 Free PMC article.
-
Buyang Huanwu Decoction Ameliorates Damage of Erectile Tissue and Function Following Bilateral Cavernous Nerve Injury.Chin J Integr Med. 2023 Sep;29(9):791-800. doi: 10.1007/s11655-022-3532-9. Epub 2022 Jun 9. Chin J Integr Med. 2023. PMID: 35679003
-
Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes.Prostate Cancer. 2014;2014:186782. doi: 10.1155/2014/186782. Epub 2014 Jun 19. Prostate Cancer. 2014. PMID: 25045541 Free PMC article.
-
Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families.Int J Cancer. 2015 May 1;136(9):2166-71. doi: 10.1002/ijc.29241. Epub 2014 Oct 13. Int J Cancer. 2015. PMID: 25273821 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical